Monday, May 23, 2022
|
13:00–14:00 |
Lunch (optional) |
|
|
14:00–14:15 |
Welcome |
Weichert / |
|
14:15–14:45 |
Program MDEB Molecular Diagnostics, Early Detection and Biomarker Development |
Heidegger / Westphalen |
|
14:15–14:30 |
Microbial metabolites as biomarkers and therapeutics in stem cell transplantation |
* Erik Thiele Orberg MD |
|
14:30–14:45 |
ctDNA profiling in B cell lymphomas |
* Stefan Alig MD |
|
14:45–15:45 |
Key Note |
von Bergwelt |
|
15:45–16:15 |
Coffee Break |
|
|
16:15–16:45 |
Program EOM Exploitation of Oncogenic Mechanisms |
Saur |
|
16:15–16:30 |
Deciperhing context-dependent fitness defects for precision |
Christian Braun MD |
|
16:30–16:45 |
Genomic NEC Landscapes for Patient-driven Disease and Vulnerability Modeling |
* Joscha Griger PhD |
| 16:45–17:00 |
|
|
|
16:45–17:00 |
Cancer AI for novel therapeutic and diagnostic approaches |
Carsten Marr PhD |
|
17:00–18:00 |
Cancer Core Structures Algül / |
|
|
17:00–17:15 |
SoO |
Sophie Dobiasch MD |
|
17:15–17:30 |
BZKF |
Prof Claus Belka MD |
|
17:30–18:00 |
Vision for Munich - Changes and Challenges in Oncology |
Prof Alexander M. M. Eggermont MD PhD |
| 18:00 | Dinner (optional) | |
Tuesday, May 24, 2022
| 9:00–9:30 | Platform CGP Cancer Genome and Proteome Analysis Platform | Küster / Greif |
| 9:00–9:15 | Robust Identification of Fusions in Tumor Transcriptomes: From AML to Solid Cancers |
* Paul Kerbs PhD |
| 9:15–9:30 | Adding a proteomic component to molecular tumor boards - INFORM-MASTER-PRO | * Julia Woortman MSc Chair of Proteomics and Bioanalytics, TUM |
| 9:30–10:15 | Joint Funding Talks |
|
| :30–10:00 | CHOICE - Characterization of the osteo-hematopoietic niche during malignant evolution |
Prof Katharina Götze MD |
| 10:00–10:15 | Immune responses in cancer patients with COVID-19 | Andreas Moosman PhD Medizinische Klinik und Poliklinik III, LMU Klinikum; Host Control of Viral Latency and Reactivation, DZIF Munich |
| 10:15–10:30 | SubPan/NEOLAP - Image-based subtyping of locally advanced pancreatic cancer | Prof Rickmer Braren MD Institut für Diagnostische Radiologie, MRI |
| 10:30–10:45 | Coffee Break | |
| 10:45–11:15 | Program EOM Exploitation of Oncogenic Mechanisms part II Haematologic Malignancies |
Jeremias / Spiekermann |
| 10:45–11:00 | Adverse stem cell clones within a single patient's tumor predict clinical outcome in AML patients | Binje Vick PhD Research Unit Apoptosis in Hematopoietic Stem Cells, HMGU |
| 11:00–11:15 |
OTUD6B is a dependency in multiple myeloma that drives S-phase entry via the RNA binding protein LIN28B |
* Ria Spallek MSc Klinik und Poliklinik für Innere Medizin III, TranslaTUM, MRI |
| 11:15–12:15 | Key Note Prof. Carsten Müller-Tidow Universität Heidelberg / DKTK Jeremias Epigenomics, epitranscriptomics and novel therapy approaches in AML |
|
| 12:15–12:30 |
Closing remarks and von Bergwelt / |
|
| Lunch (optional) |
|
|
| * Vote for Best Talk of a Young Scientist | ||
